Entities / Company
AbbVie.
pharmaceutical company
- Reports this week
- 7
- Active events
- 9
- Connections
- 519
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
AbbVie announced a joint development partnership with IGI, led by Lida Pacaud.Some support1 report
-
Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Some support1 report2 developments inside
-
A judge ruled on the exclusion of Botox from Medicare negotiations, involving AbbVie and HHS.Some support1 report
-
AbbVie and Nxera Pharma announced a collaboration to discover novel medicines.Some support1 report1 development inside
-
Nxera Pharma licensed a program to AbbVie.Some support1 report
-
AbbVie, MIT, Amgen, and John Doerr are Limited Partners in Yosemite's fund.Some support1 report
-
Market competition driven by AI and rising Treasury yields is causing market volatility involving AbbVie, Bank of America, Adobe, and Accenture.Some support1 report
-
Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.Some support1 report
-
Brise Pharmaceuticals Co., Ltd. licensed its programs to AbbVie for global development.Some support1 report
Earlier this month
-
AbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.Some support2 reports
-
MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Some support2 reports1 development inside
-
MarketBeat listed Regeneron Pharmaceuticals, AbbVie, and Moderna as stocks to watch on October 31, 2026.Some support3 reports
-
AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.Well supported5 reports1 development inside
-
Earnings reports are in focus for AbbVie, ExxonMobil, and Amazon, coinciding with a rebound in oil prices.Some support1 report
-
AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.Well supported12 reports
-
AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Speculative1 report1 development inside
-
AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.Some support1 report1 development inside
-
The FDA approved a Skyrizi regimen for Crohn's disease, based on an AFFIRM trial led by UNC.Some support1 report
-
AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Well supported5 reports1 development inside
-
AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.Well supported8 reports1 development inside
-
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Well supported3 reports4 developments inside
-
AbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.Some support1 report
-
AbbVie's drug Emrelis received approval in Brazil, alongside statistics on the high incidence of lung cancer in the country.Some support1 report
-
AbbVie reached an agreement for a drug in Canada.Some support1 report
-
Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.Some support1 report
-
Kori Wallace was appointed vice president at AbbVie.Some support2 reports
-
AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.Some support2 reports
-
Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.Some support1 report
-
AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.Some support4 reports
-
AbbVie presented research findings related to Inflammatory Bowel Disease (IBD) at the United European Gastroenterology (UEG) Week conference.Some support2 reports
-
AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Some support2 reports
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported5 reports2 developments inside
-
Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.Some support1 report
-
AbbVie presented abstracts at the American College of Gastroenterology meeting.Some support1 report
-
A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.Some support4 reports1 development inside
-
Major pharmaceutical companies are competing for investment capital.Some support1 report
-
Declining sales of Humira due to biosimilar erosion.Well supported7 reports2 developments inside
-
AbbVie and Eli Lilly are competing in the pharmaceutical market.Well supported7 reports
-
AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.Some support1 report
-
AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.Some support2 reports
One to three months ago
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Well supported3 reports3 developments inside
-
Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.Some support1 report
-
Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.Some support2 reports
-
OpenSecrets tracked donations to Virginia Foxx, who held stocks in AbbVie, in North Carolina.Some support1 report
-
Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.Some support1 report
-
AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.Some support1 report
-
AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.Well supported8 reports1 development inside
-
A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.Some support5 reports
-
MarketBeat's screener has identified a list of dividend stocks.Well supported18 reports1 development inside
-
A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.Some support3 reports1 development inside
-
AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.Some support3 reports
-
A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.Some support1 report
-
Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.Some support1 report
-
AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.Some support1 report
-
Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.Some support1 report
-
Lost patent protection for Humira in the US on August 20, 2025.Well supported11 reports
-
Pharmaceutical companies are producing testosterone replacement therapies, which are being touted as anti-aging treatments, while the U.S. military tests service members' levels.Some support2 reports1 development inside
-
AbbVie and Cisco are noted as large-cap holdings in the market.Some support1 report
-
AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.Some support2 reports1 development inside
-
Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.Some support1 report1 development inside
No events began in the chosen period. Widen it, or reset.
What's reaching AbbVie
Events traced to AbbVie, step by step, newest first- How could Galderma's board expansion affect AbbVie's market position?Galderma's board changes may signal shift in injectables strategyPossible
- Increased demand for hormone therapies may benefit AbbVieIncreased demand for hormone therapies may boost AbbVie's market viability.Possible
- Pfizer plant closure may shift market dynamics for AbbVieAbbVie may gain market share as Pfizer's drug supply chain faces long-term disruptionPossible
- AbbVie may face pressure amid JNJ's strong financial performanceAbbVie may face relative market pressure as investors favor JNJ's financial stabilityPossible
- Local elections may influence AbbVie's investment incentivesLocal elections may influence AbbVie's investment incentives in Durham CountyPossible
- Regulatory streamlining may increase competition for AbbVie's biologicsAbbVie may face increased competition as regulatory streamlining lowers market barriersPossible
See all 9 explainers
- Medicare exemption may boost AbbVie's revenue potentialMedicare exemption may boost AbbVie's revenue potentialLikely
- AbbVie may benefit from capital shift into healthcare sectorAbbVie may benefit from capital shift into healthcare sectorPossible
- Nxera Pharma's APAC expansion may influence AbbVie collaboration termsNxera Pharma's APAC expansion may influence AbbVie collaboration termsPossible
Explainers that pass through AbbVie
AbbVie is a step on the way to someone else- JNJ and AbbVie co-commercialization intensifies competition for Eli LillyIncreased competition from JNJ and AbbVie may challenge Eli Lilly's market share.Possible
- JNJ and AbbVie's IMBRUVICA deal may increase pressure on PfizerIncreased competition from JNJ and AbbVie may pressure Pfizer's market share.Possible
Around AbbVie this week
News at the entities that move AbbVie most-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves AbbVie
-
Health Canada StructuralHealth Canada approved TIL therapy for sale while the Ministry of Health denied out-of-country treatment funding.Moves AbbVie
-
Food and Drug Administration StructuralBill Clinton turned a law in 2019 that shifted regulatory control away from the Food and Drug Administration.Moves AbbVie
-
Donald Trump OperationalNPR investigated a detention plan implemented by the Trump administration, involving DHS policy officials.Moves AbbVie
-
Cantor Fitzgerald OperationalCantor Fitzgerald raised its price target and TD Cowen upgraded its rating for Expedia Group on November 7, 2026.Moves AbbVie
-
Medicare StructuralMedicare drug pricing program caused sales pressure on Publix.Moves AbbVie
Connections
The 40 strongest of 519, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Cerevel Therapeutics Structural
AbbVie successfully acquired Cerevel Therapeutics for $8.7 billion, integrating its technology into the larger entity.
-
Genmab Operational
AbbVie and Genmab maintain a formal partnership for joint drug development, clinical trials, and commercialization, including profit-sharing.
-
FDA Structural
The FDA formally regulates and grants market approvals and designations for AbbVie's pharmaceutical products.
-
Research Triangle Transactional
AbbVie plans a $1.4B investment in the Research Triangle region.
-
AstraZeneca Operational
AbbVie and AstraZeneca are direct competitors in oncology and dyslipidemia, while also engaging in strategic collaborations, such as AI initiatives.
-
Robert A. Michael Structural
Robert A. Michael serves as the CEO of AbbVie.
-
HUMIRA Structural
AbbVie's financial performance and corporate strategy were historically dependent on Humira's market status and patent lifecycle.
-
Eli Lilly and Company Operational
AbbVie and Eli Lilly are direct competitors in the pharmaceutical market, vying for market share and therapeutic dominance.
Show all 40 connections
-
Halozyme Therapeutics Structural
AbbVie utilizes proprietary ENHANZE technology licensed from Halozyme Therapeutics.
-
Health Canada Structural
Health Canada formally regulates and approves products and operations of AbbVie.
-
Food and Drug Administration Structural
AbbVie's market access and product viability are fundamentally dependent on regulatory designations and approvals from the FDA.
-
Pfizer Operational
AbbVie and Pfizer are direct competitors in the pharmaceutical market, vying for market share, investment capital, and dominance in specific therapeutic areas.
-
Donald Trump Operational
Donald Trump exerts operational influence on AbbVie through regulatory threats regarding drug prices and direct stock purchases.
-
Bristol-Myers Squibb Operational
The companies are active pharmaceutical peers engaged in market competition and collaborative research initiatives.
-
Cantor Fitzgerald Operational
Cantor Fitzgerald provides financial ratings and market commentary on AbbVie shares.
-
Johnson & Johnson Operational
AbbVie and Johnson & Johnson are direct competitors in the biopharmaceutical sector, vying for market share in oncology and immunology.
-
Cencora Structural
AbbVie utilizes Cencora as a wholesale partner to distribute a concentrated portion of its U.S. sales market.
-
Amgen Operational
AbbVie and Amgen are direct competitors and peers within the biopharmaceutical sector, particularly in the psoriatic arthritis market.
-
Medicare Structural
AbbVie's market access and pricing are structurally dependent on Medicare's coverage and negotiation decisions.
-
European Commission Structural
The European Commission formally evaluates and grants market authorization for AbbVie's pharmaceutical products in the European market.
-
SEC Structural
AbbVie must comply with SEC regulations regarding institutional investment activity and stock holdings disclosure.
-
Norges Bank Transactional
Norges Bank has repeatedly invested in and acquired stakes in AbbVie shares.
-
Royalty Pharma Structural
Royalty Pharma holds ongoing royalty rights to AbbVie's products, generating revenue from AbbVie's sales.
-
Kori Wallace Structural
Kori Wallace holds the position of Vice President at AbbVie.
-
Citadel Transactional
Citadel has significantly increased its financial stake in AbbVie shares through share purchases.
-
Lida Pacaud Operational
AbbVie and Lida Pacaud are engaged in a formal partnership for joint drug development.
-
Sanofi Operational
The companies are actively competing in the pharmaceutical market, evidenced by direct product rivalry and shared M&A pursuit.
-
ReGenX Biosciences (United States) Operational
AbbVie and ReGenX Biosciences maintain an ongoing operational partnership focused on joint drug development and clinical trials.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial ratings and price targets based on analysis of AbbVie's stock and growth prospects.
-
Securities and Exchange Commission Structural
AbbVie is subject to mandatory financial disclosure and reporting requirements enforced by the Securities and Exchange Commission.
-
Enanta Pharmaceuticals (United States) Structural
AbbVie commercializes products developed by Enanta, providing Enanta with royalty revenue and funding its operations.
-
Pharmacyclics Structural
AbbVie owns Pharmacyclics, establishing a parent-subsidiary relationship.
-
Galderma Operational
The two companies are direct competitors in the market for injectables, specifically pitting Galderma's products against AbbVie's Botox.
-
Gilgamesh Pharmaceuticals Transactional
AbbVie has repeatedly acquired drug programs and candidates from Gilgamesh Pharmaceuticals.
-
European Medicines Agency Structural
The European Medicines Agency reviews and grants market approval for AbbVie's pharmaceutical products in Europe.
-
Guggenheim Partners Transactional
AbbVie engages with Guggenheim Partners in a transactional capacity regarding corporate deals and financial matters.
-
FED Operational
FED's monetary policy, specifically interest rate changes, influences the financial characteristics and stock valuation of AbbVie.
-
Ken Griffin Transactional
Ken Griffin's fund has repeatedly purchased or increased its investment stake in AbbVie.
-
Sarah Cannon Research Institute Operational
AbbVie and Sarah Cannon Research Institute are engaged in strategic alliances and clinical trials for cancer therapy innovations.
-
Moderna Operational
AbbVie and Moderna are major competitors operating within the high-risk biotechnology and pharmaceutical sectors.
History
Events by the month they beganNovember 2026
7 events- AbbVie announced a joint development partnership with IGI, led by Lida Pacaud.
- A judge ruled on the exclusion of Botox from Medicare negotiations, involving AbbVie and HHS.
- Nxera Pharma licensed a program to AbbVie.
- AbbVie, MIT, Amgen, and John Doerr are Limited Partners in Yosemite's fund.
- Market competition driven by AI and rising Treasury yields is causing market volatility involving AbbVie, Bank of America, Adobe, and Accenture.
- Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.
- Brise Pharmaceuticals Co., Ltd. licensed its programs to AbbVie for global development.
October 2026
21 events- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.
- MarketBeat listed Regeneron Pharmaceuticals, AbbVie, and Moderna as stocks to watch on October 31, 2026.
- Earnings reports are in focus for AbbVie, ExxonMobil, and Amazon, coinciding with a rebound in oil prices.
- The FDA approved a Skyrizi regimen for Crohn's disease, based on an AFFIRM trial led by UNC.
- AbbVie is developing ABBV-466, a potential successor to Skyrizi, whose patents may expire by 2033.
- AbbVie's drug Emrelis received approval in Brazil, alongside statistics on the high incidence of lung cancer in the country.
- AbbVie reached an agreement for a drug in Canada.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.
- AbbVie presented research findings related to Inflammatory Bowel Disease (IBD) at the United European Gastroenterology (UEG) Week conference.
- AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.
- Johnson & Johnson is co-commercializing the prescription medicine IMBRUVICA with Pharmacyclics, a subsidiary of AbbVie.
- AbbVie presented abstracts at the American College of Gastroenterology meeting.
- Major pharmaceutical companies are competing for investment capital.
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Jay Korada held senior analytics roles at both AbbVie and Bristol-Myers Squibb.
- Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.
- OpenSecrets tracked donations to Virginia Foxx, who held stocks in AbbVie, in North Carolina.
- Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
September 2026
7 events- AbbVie and Cerevel Therapeutics successfully launched a new drug for Parkinson's disease, pending government coverage negotiations.
- A fund holding diverse stocks, including Canadian dividend stocks, was mentioned as part of its strategy.
- Johnson & Johnson, JPMorgan Chase, and AbbVie are dividend payers in the VYM fund.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
- Pete Sessions sold shares of Apple Inc. and AbbVie, with the transactions disclosed via SEC filings.
- AbbVie and Cisco are noted as large-cap holdings in the market.
- Multiple major pharmaceutical companies were identified as industry peers for growth during a capital markets day.
Show 3 earlier months
August 2026
3 events- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- AbbVie, Altria, and CVX are being utilized in a dividend ladder investment strategy.
June 2026
21 events- AbbVie and Nxera Pharma announced a collaboration to discover novel medicines.
- AbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- Kori Wallace was appointed vice president at AbbVie.
- AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- Declining sales of Humira due to biosimilar erosion.
- AbbVie and Eli Lilly are competing in the pharmaceutical market.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.
- MarketBeat's screener has identified a list of dividend stocks.
- A tariff plan caused market tanking on August 22, 2025, impacting publicly traded companies including Golden Entertainment and AbbVie.
- Lost patent protection for Humira in the US on August 20, 2025.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.